Fig. 1.

A Reasons for discontinuation of treatment directly preceding secukinumab initiation among patients with PsA who received treatment prior to secukinumab (N = 144); rheumatologist-reported reasons for secukinumab prescription in B all patients with PsA (N = 153) and C stratified by use of prior biologics (N = 153).

PsA psoriatic arthritis.

^aOther reason included “patient did not absorb methotrexate tabs”.

^bOther cost-related reasons included “availability of samples and Novartis assistance,” “availability of samples,” “Novartis support and samples availability,” and “samples availability”.

^cOther reasons included “job as a chef threatened by arthritis” and “patient and family preferred an injectable”